{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:12:42Z","timestamp":1778944362915,"version":"3.51.4"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>There is limited real-world evidence comparing the effectiveness of ozanimod to vedolizumab as first-line advanced therapies in patients with ulcerative colitis (UC).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a retrospective cohort study using TriNetX, a multi-institutional US database in adults with UC who were initiated on ozanimod compared to vedolizumab between January 1, 2021 and 22 June, 2024. The primary outcome was to compare the risk of a composite outcome of corticosteroid use, colectomy, or change to another advanced therapy between the 2 cohorts within 12 months. 1:1 propensity score matching (PSM) was performed for demographics, comorbid conditions, disease extent, laboratory parameters, and previous corticosteroid use. The risk was expressed as an adjusted odds ratio (aOR) with 95% CIs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We identified 222 patients in the ozanimod cohort (mean age 41.2\u2005\u00b1\u200515.7, 46.3% male sex, 68% White, and 22.5% ulcerative proctitis), and 4145 patients in the vedolizumab cohort (mean age 47.4\u2005\u00b1\u200518.3, 45.2% male sex, 69.7% White, and 17.2% ulcerative proctitis). After PSM, there was no significant difference in the risk of the composite outcome (aOR 0.92, 95% CI, 0.63-1.36) and corticosteroid use (aOR 0.80, 95% CI, 0.53-1.18) between the 2 cohorts within 12 months. There was a higher risk of change in therapy in the ozanimod cohort (aOR 1.95, 95% CI, 1.09-3.49) compared to the vedolizumab cohort. Colectomy rates were low in both cohorts (&amp;lt;0.04%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our real-world study showed that ozanimod use is associated with similar corticosteroid use but higher odds of a change in therapy compared to vedolizumab when used as first-line therapy in patients with UC. Further prospective studies are needed to understand long-term outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izae251","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T07:29:00Z","timestamp":1730359740000},"page":"1868-1875","source":"Crossref","is-referenced-by-count":7,"title":["Comparative Effectiveness of Ozanimod and Vedolizumab as First-Line Advanced Therapies in Ulcerative Colitis: A Propensity-Matched Cohort Analysis"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0597-2760","authenticated-orcid":false,"given":"Gursimran S","family":"Kochhar","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Hepatology & Nutrition, Allegheny Health Network , Pittsburgh, PA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Himsikhar","family":"Khataniar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Allegheny Health Network , Pittsburgh, PA,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8305-9742","authenticated-orcid":false,"given":"Jana G","family":"Hashash","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic , Jacksonville, FL,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fjona","family":"Tabaku","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology & Nutrition, Allegheny Health Network , Pittsburgh, PA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7681-8111","authenticated-orcid":false,"given":"Miguel","family":"Regueiro","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Cleveland Clinic Foundation , Cleveland, OH,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis A","family":"Farraye","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic , Jacksonville, FL,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6604-7712","authenticated-orcid":false,"given":"Aakash","family":"Desai","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology & Nutrition, Allegheny Health Network , Pittsburgh, PA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"issue":"10080","key":"2025070803370893700_CIT0001","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet."},{"issue":"9573","key":"2025070803370893700_CIT0002","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/s0140-6736(07)60750-8","article-title":"Inflammatory bowel disease: cause and immunobiology","volume":"369","author":"Baumgart","year":"2007","journal-title":"Lancet."},{"issue":"5","key":"2025070803370893700_CIT0003","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology."},{"issue":"5","key":"2025070803370893700_CIT0004","first-page":"265","article-title":"Sphingosine-1 phosphate receptor modulators: the next wave of oral therapies in inflammatory bowel disease","volume":"18","author":"Choden","year":"2022","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2025070803370893700_CIT0005","author":"US Food and Drug Administration"},{"issue":"12","key":"2025070803370893700_CIT0006","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.2174\/13894501113149990158","article-title":"Leukocyte traffic blockade as a therapeutic strategy in inflammatory bowel disease","volume":"14","author":"Bamias","year":"2013","journal-title":"Curr Drug Targets."},{"issue":"8","key":"2025070803370893700_CIT0007","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med."},{"issue":"13","key":"2025070803370893700_CIT0008","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/nejmoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med."},{"key":"2025070803370893700_CIT0009","first-page":"pS314","article-title":"Comparative efficacy and safety of ozanimod vs adalimumab and vedolizumab in patients with moderately to severely active ulcerative colitis","volume-title":"Am J Gastro","author":"Dubinsky","year":"2021"},{"issue":"7","key":"2025070803370893700_CIT0010","doi-asserted-by":"publisher","first-page":"S","DOI":"10.1016\/s0016-5085(22)61422-7","article-title":"Su1500: comparative efficacy and safety of ozanimod and ustekinumab in patients with moderately to severely active ulcerative colitis","volume":"162","author":"Dubinsky","year":"2022","journal-title":"Gastroenterology."},{"key":"2025070803370893700_CIT0011","doi-asserted-by":"publisher","first-page":"101866","DOI":"10.1016\/j.eclinm.2023.101866","article-title":"Comparative onset of effect of biologics and small molecules in moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"57","author":"Attauabi","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"14","key":"2025070803370893700_CIT0012","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1056\/nejmoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N Engl J Med."},{"issue":"2","key":"2025070803370893700_CIT0013","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/gutjnl-2016-312912","article-title":"Next generation of small molecules in inflammatory bowel disease","volume":"66","author":"Olivera","year":"2017","journal-title":"Gut."},{"key":"2025070803370893700_CIT0014","doi-asserted-by":"crossref","first-page":"618411","DOI":"10.3389\/fphar.2021.618411","article-title":"Advances in oral drug delivery","volume":"12","author":"Alqahtani","year":"2021","journal-title":"Front Pharmacol."},{"issue":"Suppl 17","key":"2025070803370893700_CIT0015","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12919-021-00230-7","article-title":"Intravenous versus subcutaneous delivery of biotherapeutics in IBD: an expert\u2019s and patient\u2019s perspective","volume":"15","author":"Jonaitis","year":"2021","journal-title":"BMC Proc."},{"issue":"5","key":"2025070803370893700_CIT0016","doi-asserted-by":"crossref","first-page":"e839","DOI":"10.1212\/NXI.0000000000000839","article-title":"Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS","volume":"7","author":"Harris","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"Suppl 1","key":"2025070803370893700_CIT0017","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.14309\/01.ajg.0000798724.11932.76","article-title":"P031 impact of prior biologic exposure on response to ozanimod for moderate-to-severe ulcerative colitis in the phase 3 true north study","volume":"116","author":"Sands","year":"2021","journal-title":"Am J Gastroenterol."},{"key":"2025070803370893700_CIT0018","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2147\/NRR.S427698","article-title":"A practical review for nurses and advanced practice providers","volume":"14","author":"Rubin","year":"2024","journal-title":"Nurs Res"},{"issue":"12","key":"2025070803370893700_CIT0019","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1093\/ibd\/izz059","article-title":"The role of early biologic therapy in inflammatory bowel disease","volume":"25","author":"Berg","year":"2019","journal-title":"Inflamm Bowel Dis."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izae251\/60250300\/izae251.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/7\/1868\/60250300\/izae251.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/7\/1868\/60250300\/izae251.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T07:37:12Z","timestamp":1751960232000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/31\/7\/1868\/7852968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":19,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,10,30]]},"published-print":{"date-parts":[[2025,7,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izae251","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2024,10,30]]}}}